Showing 1040 – 1050 of 1159 results
-
N-able, Inc. Initiation
William Blair initiated research coverage of N-able, Inc. (NABL $14.22). N-able sells remote monitoring and management (RMM), security and data protection, and business management solutions to managed service providers (MSPs) worldwide.
-
TWFG Inc Initiation
William Blair initiated research coverage of TWFG, Inc. (TWFG $26.30), an independent distributor of personal and commercial insurance.
-
Korro Bio Inc Initiation
William Blair initiated research coverage of Korro Bio, Inc. (KRRO $35.97), a company pioneering ADAR-based RNA-editing therapies for rare diseases with its proprietary OPERA platform.
-
Fstar Therapeutics Inc and Merus NV Initiation
William Blair initiated research coverage of F-star Therapeutics, Inc. (FSTX $10.37) and Merus N.V. (MRUS $23.00), which are developing immuno-oncology therapies in the evolving field of bispecific and multispecific antibodies.
-
Privia Health Group Inc Initiation
William Blair initiated research coverage of Privia Health Group, Inc. (PRVA $30.08), a technology-enabled care management organization. Privia works with more than 2,700 providers and helps manage more than 3 million patients under a wide variety of fee-for-service and value-based care delivery arrangements.
-
Vaccitech plc Initiation
William Blair initiated research coverage of Vaccitech plc (VACC $14.58). Vaccitech is a clinical-stage biotechnology company that develops immunotherapeutics by leveraging its proprietary chimpanzee adenovirus and Modified Vaccinia Ankara T-cell-inducing platform. Areas of focus include therapeutic and prophylactic programs in the infectious disease and oncology space.
-
Primo Water Corporation Initiation
William Blair initiated research coverage of Primo Water Corporation (PRMW $27.67), a leading North America–focused pure-play water solutions provider.
-
Alto Neuroscience Inc Initiation
William Blair initiated research coverage of Alto Neuroscience, Inc. (ANRO $13.72), a company focused on developing novel therapies for high-unmet-need indications in psychiatry supported by AI-enabled precision approaches to identify response biomarkers.
-
Keros Therapeutics Inc Initiation
William Blair initiated research coverage of Keros Therapeutics, Inc. (KROS $59.49), a company focused on the development of novel therapies targeting the TGF-β superfamily of cytokines, which play essential roles in the proliferation and differentiation of numerous cell types.
-
AAR Corp Initiation
William Blair initiated research coverage of AAR Corp. (AIR $57.14), a provider of supply chain and maintenance, repair, and overhaul (MRO) services for commercial aviation and government customers.